A key disconnect exists between clinical and radiological response to niragasestat. Patients often experience rapid symptomatic relief, such as pain reduction, within days or weeks. Clinicians should expect a significant delay before seeing tumor shrinkage on imaging, with a median time to response of 5.6 months.

Even when desmoid tumor patients seem to tolerate niragacestat well, they often report a surprising improvement in well-being after discontinuing the drug. This reveals a subtle, cumulative quality-of-life impact from low-grade toxicities that may not be fully appreciated by patients or clinicians during active treatment.

Data from the Checkmate 743 trial shows that patients who stopped dual immunotherapy (Nivo/Ipi) due to toxicity can still achieve long-term benefits. A third of these patients had an ongoing response at three years, despite stopping treatment after only four months on average, providing confidence in the regimen.

Though ADCs like Sacituzumab Govitekan cause notable side effects like diarrhea and neutropenia, patient-reported outcome data shows they provide a meaningful and sustained improvement in quality of life compared to standard chemotherapy. This was observed even with longer treatment durations and lower discontinuation rates.

The Phase 2 TRAIT study suggests starting adjuvant abemaciclib at a lower dose and escalating over several weeks significantly reduces early discontinuations due to side effects like diarrhea. This strategy helps more patients get through the initial high-toxicity period and remain on the effective dose for the full two-year course.

Patients on niragacestat for desmoid tumors often experience rapid symptom improvement. However, this clinical benefit significantly precedes radiological response (tumor shrinkage on scans), which can take over five months to appear. This disconnect is crucial for managing patient expectations and assessing early treatment efficacy.

In rare NRG1-fusion positive cancers, targeted therapy shows a modest 29% objective response rate, below the typical 40% benchmark for accelerated approval. However, the median duration of response is nearly a year (and 1.5 years in naive patients), making it a highly effective, life-altering therapy for responders. This highlights duration, not just rate, as a key efficacy metric.

There is no standard duration for systemic therapies like niragacestat. Clinicians often aim for 6-12 months, potentially extending to two years. The decision to stop is subjective and arbitrary, balancing treatment side effects against disease symptoms, highlighting the need for individualized approaches rather than fixed protocols.

Data from the MONARCH-E and NATALY trials show that the benefit of adjuvant CDK4/6 inhibitors like abemaciclib and ribociclib persists and even increases after patients complete their 2-3 year treatment course. This sustained "carryover effect" suggests a lasting impact on disease biology rather than just temporary suppression.